{"id":43264,"date":"2025-10-14T15:32:54","date_gmt":"2025-10-14T07:32:54","guid":{"rendered":"https:\/\/flcube.com\/?p=43264"},"modified":"2025-10-14T15:32:55","modified_gmt":"2025-10-14T07:32:55","slug":"ucb-biosciences-receives-nmpa-marketing-authorization-for-zilucoplan-zilbrysq-in-adult-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43264","title":{"rendered":"UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis"},"content":{"rendered":"\n

UCB S.A.<\/strong> (EBR: UCB<\/a>), a global biopharmaceutical company, announced today that the National Medical Products Administration (NMPA) has approved the marketing authorization for Zilucoplan (brand name: Zilbrysq)<\/strong> in combination with standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti\u2011acetylcholine receptor (AChR) antibody positive.<\/p>\n\n\n\n

Key Highlights<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>UCB S.A.<\/td><\/tr>
Product<\/strong><\/td>Zilucoplan (Zilbrysq)<\/td><\/tr>
Regulatory Body<\/strong><\/td>China NMPA<\/td><\/tr>
Indication<\/strong><\/td>Adult gMG, AChR\u2011positive<\/td><\/tr>
Administration<\/strong><\/td>Once\u2011daily, subcutaneous, self\u2011administered<\/td><\/tr>
Unique Feature<\/strong><\/td>First home\u2011administered C5 inhibitor for gMG<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What Is Zilucoplan?<\/h2>\n\n\n\n

Zilucoplan is a once\u2011daily, self\u2011administered, subcutaneous peptide inhibitor that targets complement component\u202f5 (C5). It is the only self\u2011administered targeted C5 inhibitor therapy for gMG, preventing complement\u2011mediated damage at the neuromuscular junction. Patients can complete the injection at home in just 5\u20118\u202fseconds, offering a convenient and effective addition to standard gMG treatment regimens.<\/p>\n\n\n\n

Market Impact in China<\/h2>\n\n\n\n